Chris N. Culvern

Chris N. Culvern

Auto-generated profile, based on publicly available information

Chris N. Culvern

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
KBKevin C. Bigart
Kevin C. Bigart
CNCindy R. Nahhas
Cindy R. Nahhas
GRGregory P. Ruzich
Gregory P. Ruzich
CCChris N. Culvern
Chris N. Culvern
MSMichael B. Salzano
Michael B. Salzano
DNDenis Nam
Denis Nam

1 June 2021 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
CNCindy R. Nahhas
Cindy R. Nahhas
PCPeter N. Chalmers
Peter N. Chalmers
JPJavad Parvizi
Javad Parvizi
SSScott M. Sporer
Scott M. Sporer
GDGregory K. Deirmengian
Gregory K. Deirmengian
CVCraig J. Della Valle
Craig J. Della Valle

28 September 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
RSRobert A. Sershon
Robert A. Sershon
YFYale A. Fillingham
Yale A. Fillingham
MAMatthew P. Abdel
Matthew P. Abdel
AMArthur L. Malkani
Arthur L. Malkani
RSRan Schwarzkopf
Ran Schwarzkopf
TGThe Hip Society Research Group
The Hip Society Research Group
Background: The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty. Methods: Six centers prospectively randomized 175 patients to 1 of 4 regimens: (1) 1-g intravenous (IV) TXA prior to incision (the single-dose IV group), (2) 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (the double-dose IV group), (3) a combination of 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (the combined IV and topical group), or (4) 3 doses totaling 1,950-mg oral TXA (the multidose oral group). Randomization was based on revision subgroups to ensure equivalent group distribution. An a priori power analysis (α = 0.05; β = 0.80) determined that 40 patients per group were required to identify a >1-g/dL difference in postoperative hemoglobin reduction between groups. Per-protocol analysis involved an analysis of variance, Fisher exact tests, and two 1-sided t tests for equivalence. Demographic and surgical variables were equivalent between groups. Results: No significant differences were found between TXA regimens when evaluating reduction in hemoglobin (3.4 g/dL for the single-dose IV group, 3.6 g/dL for the double-dose IV group, 3.5 g/dL for the combined IV and topical group, and 3.4 g/dL for the multidose oral group; p = 0.95), calculated blood loss (p = 0.90), or transfusion rates (14% for the single-dose IV group, 18% for the double-dose IV group, 17% for the combined group, and 17% for the multidose oral group; p = 0.96). Equivalence testing revealed that all possible pairings were statistically equivalent, assuming a >1-g/dL difference in hemoglobin reduction as clinically relevant. There was 1 venous thromboembolism, with no differences found between groups (p = 1.00). Conclusions: All 4 TXA groups tested had equivalent blood-sparing properties in the setting of revision total hip arthroplasty, with a single venous thromboembolism reported in this high-risk population. Based on the equivalence between groups, surgeons should utilize whichever of the 4 investigated regimens is best suited for their practice and hospital setting. Given the transfusion rate in revision total hip arthroplasty despite TXA utilization, further work is required in this area. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.